XOMA Royalty Corp

Analysis for Ticker: XOMA

Xoma Royalty Corp operates as a financial middleman that buys rights to future medicine payments from drug candidates like Vabysmo and Ojemda, letting large pharmaceutical companies pay for the expensive science while it waits to collect a check. But the check is already spent. The company sits on a staggering 1,2$ billion accumulated deficit. The core mechanism is not a business, but a financial drain where special instruments called cumulative perpetual preferred shares act like private cups that catch all the cash before anyone else can have a drink. Think of it like a bank account that owes a never-ending 8,625% and 8,375% fee every single year. Even if the account is empty, the bill just keeps growing until the next deposit arrives, ensuring the common owners are always mathematically last in line. The extraction intensified on 15/08/2025, when the company used 1,04$ in cash and a promise of future money to swallow LAVA Therapeutics. By 20/11/2025, anyone who did not want to sell was forced to let go of their shares for that same 1,04$ price through a downstream merger. On 12/11/2025, the company showed it was bleeding through its arteries. A lender named Blue Owl Capital held 108,7$ million in debt and took 11,9$ million in actual cash for interest in just nine months. The preferred shares drained another 4,1$ million, while the company only made 8,3$ million from its actual work. Unrestricted cash collapsed from 101,6$ million down to 45,1$ million as they also got stuck with a 41,7$ million office lease.